Ocuphire Pharma Stock Beta
| OCUPDelisted Stock | USD 1.13 0.06 5.04% |
Ocuphire Pharma fundamentals help investors to digest information that contributes to Ocuphire Pharma's financial success or failures. It also enables traders to predict the movement of Ocuphire Stock. The fundamental analysis module provides a way to measure Ocuphire Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ocuphire Pharma stock.
Ocuphire |
Ocuphire Pharma Company Beta Analysis
Ocuphire Pharma's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Ocuphire Pharma Beta | 0.31 |
Most of Ocuphire Pharma's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ocuphire Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Ocuphire Pharma has a Beta of 0.309. This is 64.07% lower than that of the Biotechnology sector and 77.77% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Ocuphire Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ocuphire Pharma's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ocuphire Pharma could also be used in its relative valuation, which is a method of valuing Ocuphire Pharma by comparing valuation metrics of similar companies.Ocuphire Pharma is currently under evaluation in beta category among its peers.
As returns on the market increase, Ocuphire Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Ocuphire Pharma is expected to be smaller as well.
Ocuphire Fundamentals
| Return On Equity | -0.36 | |||
| Return On Asset | -0.21 | |||
| Profit Margin | (0.86) % | |||
| Operating Margin | (7.49) % | |||
| Current Valuation | (6.57 M) | |||
| Shares Outstanding | 26.2 M | |||
| Shares Owned By Insiders | 7.33 % | |||
| Shares Owned By Institutions | 10.44 % | |||
| Number Of Shares Shorted | 930.64 K | |||
| Price To Book | 0.86 X | |||
| Price To Sales | 2.12 X | |||
| Revenue | 19.05 M | |||
| Gross Profit | (14.58 M) | |||
| EBITDA | (10.56 M) | |||
| Net Income | (9.99 M) | |||
| Cash And Equivalents | 17.15 M | |||
| Cash Per Share | 0.83 X | |||
| Total Debt | 4.04 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 5.41 X | |||
| Book Value Per Share | 1.56 X | |||
| Cash Flow From Operations | (1.11 M) | |||
| Short Ratio | 10.10 X | |||
| Earnings Per Share | (0.54) X | |||
| Target Price | 16.75 | |||
| Number Of Employees | 14 | |||
| Beta | 0.31 | |||
| Market Capitalization | 34.84 M | |||
| Total Asset | 53.95 M | |||
| Retained Earnings | (81.47 M) | |||
| Working Capital | 49.91 M | |||
| Net Asset | 53.95 M |
About Ocuphire Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ocuphire Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ocuphire Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ocuphire Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Ocuphire Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ocuphire Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ocuphire Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Ocuphire Stock
Moving against Ocuphire Stock
| 0.86 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.86 | HD | Home Depot | PairCorr |
| 0.8 | PTAIF | PT Astra International | PairCorr |
| 0.78 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
| 0.71 | SSNLF | Samsung Electronics | PairCorr |
The ability to find closely correlated positions to Ocuphire Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ocuphire Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ocuphire Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ocuphire Pharma to buy it.
The correlation of Ocuphire Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ocuphire Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ocuphire Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ocuphire Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Ocuphire Stock
If you are still planning to invest in Ocuphire Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ocuphire Pharma's history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |